Erbitux
cetuximab · EGFR Inhibitor / Monoclonal Antibody
Indications & Uses
KRAS wild-type metastatic colorectal cancer (mCRC) in combination with chemotherapy or as a single agent; locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) in combination with radiation.
Contraindications
None.
Side Effects & Warnings
Infusion-related reactions, cardiopulmonary arrest, dermatologic toxicity (acneiform rash), hypomagnesemia, and paronychia.
Drug & Dietary Interactions
Increased incidence of severe diarrhea when combined with fluoropyrimidines and irinotecan.
Regulatory & Prescribing Information
FDA Approved Biologic (BLA 125084). Black Box Warning for Infusion Reactions and Cardiopulmonary Arrest.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.